NVS

Broker Darlings of the Dow: Pfizer Inc. (PFE)

A study of recommendations at the major brokerages shows Pfizer is the #7 broker pick, out of the 30 stocks in the Dow More 

Johnson & Johnson: My Favorite Dividend King (JNJ)

Johnson & Johnson is one of the strongest dividend payers the market's have to offer. Here's why I'm willing to pay a premium to own JNJ stock More 

Intellia Therapeutics IPO: The “Biggest Biotech Discovery of the Century”

Intellia Therapeutics' upcoming IPO could bring "the biggest biotech discovery of the century" to a down-and-out biotech sector. More 

Novartis AG (ADR) (NVS) Under Investigation for ‘Sham’ Events

Novartis is under investigation for alleged 80,000 sham events it held for doctors as part of a case concerning illegal kickbacks. More 

Why Johnson & Johnson Is a Top Dow Pick (JNJ)

A study of analyst recommendations shows that Johnson & Johnson is the #17 broker pick, on average, out of the 30 stocks making up the Dow More 

STUDY: Dementia Risk Linked to Popular Heartburn Drugs

Several heartburn drugs known as proton pump inhibitors are being linked to increased risk of dementia, according to a study published JAMA Neurology. More 

Novartis (NVS) Stock Falls on Earnings Miss

Novartis stock dropped on Wednesday after it missed earnings estimates set by analysts for it in the fourth quarter of 2015. More